HEMOSTEMIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.045 CAD | +12.50% |
|
-10.00% | -35.71% |
Presenter SpeechThomas Smeenk (Executives)Welcome to the Annual General and Special Meeting of...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patientâs blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patientâs blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
Calendar
2024-04-29
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.71% | 2.86M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HEM Stock
- News Hemostemix Inc.
- Transcript : Hemostemix Inc. - Shareholder/Analyst Call
